市場調查報告書

全球口服抗糖尿病藥市場:按藥物和地區分列的未來預測

Global Oral Antidiabetic Drugs Market Size study, by Drug and Regional Forecasts 2020-2027

出版商 Bizwit Research & Consulting LLP 商品編碼 943653
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
全球口服抗糖尿病藥市場:按藥物和地區分列的未來預測 Global Oral Antidiabetic Drugs Market Size study, by Drug and Regional Forecasts 2020-2027
出版日期: 2020年06月05日內容資訊: 英文
簡介

預計全球口服抗糖尿病藥市場將在2019年達到約268億美元,到2020-2027年增長率超過10.3%。世界上糖尿病患者的數量正在增加,人口正在老齡化。另一方面,大型製藥公司正在集中精力開發新型冠狀病毒(Covid-19)疫苗,這可能會延遲口服抗糖尿病藥的開發。

本報告分析了全球口服糖尿病治療市場,並分析了市場的基本結構(例如價值鏈),主要驅動因素和製約因素以及整個市場規模(未來八年)的趨勢展望。按藥品和地區劃分的詳細趨勢,主要公司的概況,市場份額以及其他信息。

第1章執行摘要

第2章全球阻斷式對策市場:定義和範圍

第3章全球阻斷式對策市場:市場動態

  • 對阻斷式對策市場的影響分析

第4章全球人臉識別市場:行業分析

  • 波特的五力分析
  • PEST分析
  • 投資/引進模型
  • 分析師的建議和結論

第5章按藥物劃分的全球口服抗糖尿病藥市場

  • 市場概況
  • 按藥物分類的市場表現:未來潛力分析
  • 市場估計/預測:按藥品(基於價值)
  • 細分分析
    • 雙胍
    • Alpha-葡萄糖甘□抑製劑
    • 多巴胺D2受體激動劑
    • 鋰鈉葡萄糖共轉運2(SGLT-2)抑製劑
    • 二□基□□-4(DPP-4)抑製劑
    • 磺尿類
    • Meglitinide

第6章全球口服抗糖尿病藥市場:區域分析

  • 口服抗糖尿病藥市場:按地區劃分的市場概況
  • 北美市場
    • 美國
    • 加拿大
  • 歐洲市場
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲國家
  • 亞太市場
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 其他亞太國家
  • 拉丁美洲市場
    • 巴西
    • 墨西哥
  • 其他國家/地區的市場(RoW)

第7章公司信息

  • 主要市場策略
  • 公司簡介
    • Takeda Pharmaceutical Company Ltd.
    • Pfizer Inc.
    • Eli Lilly and Company
    • Janssen Pharmaceutica
    • Astellas Pharma
    • Boehringer Ingelheim Group
    • Merck & Co., Inc.,
    • AstraZeneca plc
    • Novartis International AG
    • Sanofi S.A.

第8章調查過程

目錄

Title:
Global Oral Antidiabetic Drugs Market Size study, by Drug (Biguanides, Alpha-glucosidase inhibitors, Dopamine-D2 Receptor Agonist, Sodium - glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, Meglitinides) and Regional Forecasts 2020-2027.

Global Oral Antidiabetic Drugs Market is valued at approximately USD 26.8 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 10.3% over the forecast period 2020-2027. Oral anti-diabetic drugs can be defined as a medication consumed orally which are recommended to heal diabetes mellitus (type 2). It treats diabetes mellitus by reducing the level of blood sugar level. These drugs often known as oral antihyperglycemic agents or oral hypoglycemic agents. Oral anti-diabetic drugs are also recommended as monotherapy, however in acute cases, and can be provided in blend with insulin. Rising incidences of diabetes across the globe, increasing aging population, and rapidly growing research and development efforts by pharmaceutical manufacturers to promote the demand for oral drugs are the few other factors driving the market growth during the forecast period. According to the International Diabetic Federation (IDF), the prevalence of diabetes among adults (20-79 years) was about 463 million adults in 2019, and this estimation is likely to grow almost 700 million by the year 2045. Similarly, as per the IDF Diabetes Atlas in 2019, the number of diabetic patients in Europe is expected to reach around 68 million by 2045, with total health expenditure for diabetes almost USD 214 billion. This, in turn, is expected to accelerate the usage of Oral Antidiabetic Drugs all over the world. Amidst the COVID-19 outbreak around the world, the pharma industry is more concerned about the development of the COVID-19 vaccine, thus, R&D efforts for oral antidiabetic drugs is substantially decline. Though, the demand for oral anti-diabetic drugs is not affecting, and it is high as much as before the COVID-19 crisis. Therefore, the market will boost at a significant rate in the forthcoming years. However, the high cost of oral antidiabetic drugs is one of the major factors impeding the growth of the market over the forecast period of 2020-2027.

The regional analysis of the global Oral Antidiabetic Drugs market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the rising prevalence of diabetes, coupled with the introduction of new anti-diabetic drugs with improve efficacy in the region. Whereas, Asia-Pacific is also anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as growing diabetic population, coupled with improving healthcare infrastructure would create lucrative growth prospects for the demand of Oral Antidiabetic Drugs in the region.

Major market player included in this report are:

Takeda Pharmaceutical Company Ltd.

Pfizer Inc.

Eli Lilly and Company

Janssen Pharmaceutica

Astellas Pharma

Boehringer Ingelheim Group

Merck & Co., Inc.,

AstraZeneca plc

Novartis International AG

Sanofi S.A.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug:

Biguanides

Alpha-glucosidase inhibitors

Dopamine -D2 Receptor Agonist

Sodium - glucose Cotransport -2 (SGLT-2) inhibitor

Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors

Sulfonylureas

Meglitinides

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018

Base year - 2019

Forecast period - 2020 to 2027

Target Audience of the Global Oral Antidiabetic Drugs Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
    • 1.2.1. Oral Antidiabetic Drugs Market, by Region, 2018-2027 (USD Billion)
    • 1.2.2. Oral Antidiabetic Drugs Market, by Drug, 2018-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Oral Antidiabetic Drugs Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Oral Antidiabetic Drugs Market Dynamics

  • 3.1. Oral Antidiabetic Drugs Market Impact Analysis (2018-2027)
    • 3.1.1. Market Drivers
    • 3.1.2. Market Challenges
    • 3.1.3. Market Opportunities

Chapter 4. Global Oral Antidiabetic Drugs Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2017-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Oral Antidiabetic Drugs Market, by Drug

  • 5.1. Market Snapshot
  • 5.2. Global Oral Antidiabetic Drugs Market by Drug, Performance - Potential Analysis
  • 5.3. Global Oral Antidiabetic Drugs Market Estimates & Forecasts by Drug 2017-2027 (USD Billion)
  • 5.4. Oral Antidiabetic Drugs Market, Sub Segment Analysis
    • 5.4.1. Biguanides
    • 5.4.2. Alpha-glucosidase inhibitors
    • 5.4.3. Dopamine -D2 Receptor Agonist
    • 5.4.4. Sodium - glucose Cotransport -2 (SGLT-2) inhibitor
    • 5.4.5. Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
    • 5.4.6. Sulfonylureas
    • 5.4.7. Meglitinides

Chapter 6. Global Oral Antidiabetic Drugs Market, Regional Analysis

  • 6.1. Oral Antidiabetic Drugs Market, Regional Market Snapshot
  • 6.2. North America Oral Antidiabetic Drugs Market
    • 6.2.1. U.S. Oral Antidiabetic Drugs Market
      • 6.2.1.1. Drug breakdown estimates & forecasts, 2017-2027
    • 6.2.2. Canada Oral Antidiabetic Drugs Market
  • 6.3. Europe Oral Antidiabetic Drugs Market Snapshot
    • 6.3.1. U.K. Oral Antidiabetic Drugs Market
    • 6.3.2. Germany Oral Antidiabetic Drugs Market
    • 6.3.3. France Oral Antidiabetic Drugs Market
    • 6.3.4. Spain Oral Antidiabetic Drugs Market
    • 6.3.5. Italy Oral Antidiabetic Drugs Market
    • 6.3.6. Rest of Europe Oral Antidiabetic Drugs Market
  • 6.4. Asia-Pacific Oral Antidiabetic Drugs Market Snapshot
    • 6.4.1. China Oral Antidiabetic Drugs Market
    • 6.4.2. India Oral Antidiabetic Drugs Market
    • 6.4.3. Japan Oral Antidiabetic Drugs Market
    • 6.4.4. Australia Oral Antidiabetic Drugs Market
    • 6.4.5. South Korea Oral Antidiabetic Drugs Market
    • 6.4.6. Rest of Asia Pacific Oral Antidiabetic Drugs Market
  • 6.5. Latin America Oral Antidiabetic Drugs Market Snapshot
    • 6.5.1. Brazil Oral Antidiabetic Drugs Market
    • 6.5.2. Mexico Oral Antidiabetic Drugs Market
  • 6.6. Rest of The World Oral Antidiabetic Drugs Market

Chapter 7. Competitive Intelligence

  • 7.1. Top Market Strategies
  • 7.2. Company Profiles
    • 7.2.1. Takeda Pharmaceutical Company Ltd.
      • 7.2.1.1. Key Information
      • 7.2.1.2. Overview
      • 7.2.1.3. Financial (Subject to Data Availability)
      • 7.2.1.4. Product Summary
      • 7.2.1.5. Recent Developments
    • 7.2.2. Pfizer Inc.
    • 7.2.3. Eli Lilly and Company
    • 7.2.4. Janssen Pharmaceutica
    • 7.2.5. Astellas Pharma
    • 7.2.6. Boehringer Ingelheim Group
    • 7.2.7. Merck & Co., Inc.,
    • 7.2.8. AstraZeneca plc
    • 7.2.9. Novartis International AG
    • 7.2.10. Sanofi S.A.

Chapter 8. Research Process

  • 8.1. Research Process
    • 8.1.1. Data Mining
    • 8.1.2. Analysis
    • 8.1.3. Market Estimation
    • 8.1.4. Validation
    • 8.1.5. Publishing
  • 8.2. Research Attributes
  • 8.3. Research Assumption

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, REPORT SCOPE
  • TABLE 2. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY REGION 2017-2027 (USD BILLION)
  • TABLE 3. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY DRUG 2017-2027 (USD BILLION)
  • TABLE 4. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 5. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 6. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 7. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 8. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 9. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 10. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 11. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 12. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 13. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 14. U.S. ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 15. U.S. ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 16. U.S. ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 17. CANADA ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 18. CANADA ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 19. CANADA ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 20. UK ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 21. UK ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 22. UK ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 23. GERMANY ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 24. GERMANY ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 25. GERMANY ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 26. ROE ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 27. ROE ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 28. ROE ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 29. CHINA ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 30. CHINA ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 31. CHINA ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 32. INDIA ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 33. INDIA ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 34. INDIA ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 35. JAPAN ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 36. JAPAN ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 37. JAPAN ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 38. ROAPAC ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 39. ROAPAC ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 40. ROAPAC ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 41. BRAZIL ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 42. BRAZIL ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 43. BRAZIL ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 44. MEXICO ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 45. MEXICO ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 46. MEXICO ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 47. ROLA ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 48. ROLA ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 49. ROLA ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 50. ROW ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 51. ROW ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 52. ROW ORAL ANTIDIABETIC DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 53. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL ORAL ANTIDIABETIC DRUGS MARKET
  • TABLE 54. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL ORAL ANTIDIABETIC DRUGS MARKET
  • TABLE 55. YEARS CONSIDERED FOR THE STUDY
  • TABLE 56. EXCHANGE RATES CONSIDERED

LIST OF FIGURES

  • FIG 1. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, RESEARCH METHODOLOGY
  • FIG 2. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, MARKET ESTIMATION TECHNIQUES
  • FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
  • FIG 4. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, KEY TRENDS 2019
  • FIG 5. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, GROWTH PROSPECTS 2020-2027
  • FIG 6. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, PORTERS 5 FORCE MODEL
  • FIG 7. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, PEST ANALYSIS
  • FIG 8. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, VALUE CHAIN ANALYSIS
  • FIG 9. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 10. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 11. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 12. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 13. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 14. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, REGIONAL SNAPSHOT 2017 & 2027
  • FIG 15. NORTH AMERICA ORAL ANTIDIABETIC DRUGS MARKET 2017 & 2027 (USD BILLION)
  • FIG 16. EUROPE ORAL ANTIDIABETIC DRUGS MARKET 2017 & 2027 (USD BILLION)
  • FIG 17. ASIA PACIFIC ORAL ANTIDIABETIC DRUGS MARKET 2017 & 2027 (USD BILLION)
  • FIG 18. LATIN AMERICA ORAL ANTIDIABETIC DRUGS MARKET 2017 & 2027 (USD BILLION)
  • FIG 19. GLOBAL ORAL ANTIDIABETIC DRUGS MARKET, COMPANY MARKET SHARE ANALYSIS (2019)